within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EK01_Axitinib;

model Axitinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.58,
    Cl = 3.888888888888889e-06,
    adminDuration = 600,
    adminMass = 5 / 1000000,
    adminCount = 1,
    Vd = 0.047,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.007500000000000001,
    Tlag = 25.2,
    Vdp = 0.139,
    k12 = 1.0833333333333334e-05,
    k21 = 1.0833333333333334e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Axitinib</td></tr><tr><td>ATC code:</td><td>L01EK01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>47</td><td>L</td></tr>
    <tr><td>clearance:</td><td>14</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Axitinib is an oral, small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3. It is primarily used for the treatment of advanced renal cell carcinoma and is approved for use in several countries, including the United States and the European Union.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic analysis in adult patients with solid tumors, including renal cell carcinoma, with oral administration. Data represents a typical adult (mean weight ~70 kg) without severe hepatic or renal impairment.</p><h4>References</h4><ol><li><p>Chen, Y, et al., &amp; Pithavala, YK (2015). Axitinib plasma pharmacokinetics and ethnic differences. <i>Investigational new drugs</i> 33(2) 521–532. DOI:<a href=\"https://doi.org/10.1007/s10637-015-0214-x\">10.1007/s10637-015-0214-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25663295/\">https://pubmed.ncbi.nlm.nih.gov/25663295</a></p></li><li><p>Chen, Y, et al., &amp; Pithavala, YK (2013). Clinical pharmacology of axitinib. <i>Clinical pharmacokinetics</i> 52(9) 713–725. DOI:<a href=\"https://doi.org/10.1007/s40262-013-0068-3\">10.1007/s40262-013-0068-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23677771/\">https://pubmed.ncbi.nlm.nih.gov/23677771</a></p></li><li><p>Chen, Y, et al., &amp; Hu, P (2011). A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 49(11) 679–687. DOI:<a href=\"https://doi.org/10.5414/cp201570\">10.5414/cp201570</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22011693/\">https://pubmed.ncbi.nlm.nih.gov/22011693</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EK01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Axitinib;
